Watchdog approves skin cancer drugs ipilimumab and vemurafenib

 

Patients with an advanced form of skin cancer were given new hope today after the health watchdog recommended that two life-extending treatments should be available on the NHS.

In final draft guidance, the National Institute for Health and Clinical Excellence (Nice) said that drugs ipilimumab and vemurafenib should be used for the treatment of advanced malignant melanoma - the most dangerous type of skin cancer.

The prognosis for advanced melanoma is very poor, and those who are diagnosed often have just months to live.

But under new proposals, patients in England and Wales will be able to access the life-extending treatments.

"Advanced melanoma can significantly affect patients' quality of life and without effective new therapies, the prognosis for advanced disease is very poor," said Professor Carole Longson, director at the Health Technology Evaluation Centre at Nice.

"For many years the treatments available for this condition have been very limited and in some cases restricted to palliative care. However, there are now a number of new treatments being developed and vemurafenib and ipilimumab are the first two that Nice has been asked to review.

"These new draft recommendations represent really good news for skin cancer patients.

"Vemurafenib and ipilimumab are breakthrough treatments that can potentially significantly affect prognosis for these patients and we are very pleased that the manufacturers have worked with us so that we are now able to recommend both ipilimumab and vemurafenib."

In initial guidance, Nice did not recommend the use of the treatments. But the watchdog has since received data about the cost effectiveness of the drugs and in its final draft guidance it has recommended the treatments on the basis that the manufacturers provide them with a discount.

Vemurafenib, which is also known as zelboraf and is manufactured by Roche, has been recommended for the treatment of metastatic melanoma.

And ipilimumab, made by Bristol-Myers Squibb, is recommended for the treatment of advanced malignant melanoma in people who have received prior chemotherapy.

Patient Richard Jackson, 44, who was diagnosed with metastatic malignant melanoma in 2006, said that ipilimumab, also known as yervoy, gave him a chance to see his two children grow up.

Mr Jackson, from Little Sutton, Wirral, Cheshire, said: "Being diagnosed with metastatic malignant melanoma in 2006 gave me very little chance of long-term survival.

"No standard treatment existed, and the only course of action was to agree to undergo trials.

"The compassionate use programme allowed me to be treated with yervoy in 2007. The effects were instant and dramatic, skin lesions, about the size of golf balls, flushed with colour and visibly reduced.

"Although the side effects were debilitating, by November 2008 I was back at work and living cancer free.

"Yervoy gave me hope and inspired me to keep going. Without Yervoy there is little chance I would still be here to see my two children grow up."

Until Nice issues final guidance on the drugs, NHS bodies should make decisions locally on the funding of specific treatments, a spokeswoman said.

Professor Alan Ashworth, chief executive of the London-based Institute of Cancer Research, said: "It represents a great stride forward in the treatment of advanced malignant melanoma, and is a brilliant example of what new-generation targeted cancer therapies can achieve.

"Zelboraf validates the importance of research into the fundamental causes of cancer, since it works by blocking a very specific mutant molecule that fuels the growth and spread of melanomas.

"It can take time to move research from the laboratory into the clinic, but zelboraf today becomes the latest in a string of targeted cancer therapies that will deliver real benefits for NHS patients."

Gill Nuttall, spokeswoman for the patient support group Factor 50, added: "I am absolutely delighted that Nice have overturned their original decision and that the patients I speak to every day can start to get the treatments that they so desperately need.

"Some of the patients who were here at the time of the original decision are sadly no longer with us and today will be tinged with sadness for some people.

"I am really pleased that Nice paid attention to all the comments made by the patients and clinicians and that those patients can now start to benefit from this innovative new treatment."

Nina Goad, spokeswoman for the British Association of Dermatologists, added: "The medicines may extend the lives of some of those with widespread melanoma who otherwise would have had little treatment available to help their advanced disease."

PA

Life and Style
ebookNow available in paperback
ebooks
ebookA delicious collection of 50 meaty main courses
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
SPONSORED FEATURES

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Recruitment Genius: Technical Author / Multimedia Writer

    Negotiable: Recruitment Genius: This recognized leader in providing software s...

    Recruitment Genius: Clinical Lead / RGN

    £40000 - £42000 per annum: Recruitment Genius: This is an exciting opportunity...

    Recruitment Genius: IT Sales Consultant

    £35000 - £40000 per annum: Recruitment Genius: This IT support company has a n...

    Recruitment Genius: Works Engineer

    Negotiable: Recruitment Genius: A works engineer is required in a progressive ...

    Day In a Page

    Isis profits from destruction of antiquities by selling relics to dealers - and then blowing up the buildings they come from to conceal the evidence of looting

    How Isis profits from destruction of antiquities

    Robert Fisk on the terrorist group's manipulation of the market to increase the price of artefacts
    Labour leadership: Andy Burnham urges Jeremy Corbyn voters to think again in last-minute plea

    'If we lose touch we’ll end up with two decades of the Tories'

    In an exclusive interview, Andy Burnham urges Jeremy Corbyn voters to think again in last-minute plea
    Tunisia fears its Arab Spring could be reversed as the new regime becomes as intolerant of dissent as its predecessor

    The Arab Spring reversed

    Tunisian protesters fear that a new law will whitewash corrupt businessmen and officials, but they are finding that the new regime is becoming as intolerant of dissent as its predecessor
    King Arthur: Legendary figure was real and lived most of his life in Strathclyde, academic claims

    Academic claims King Arthur was real - and reveals where he lived

    Dr Andrew Breeze says the legendary figure did exist – but was a general, not a king
    Who is Oliver Bonas and how has he captured middle-class hearts?

    Who is Oliver Bonas?

    It's the first high-street store to pay its staff the living wage, and it saw out the recession in style
    Earth has 'lost more than half its trees' since humans first started cutting them down

    Axe-wielding Man fells half the world’s trees – leaving us just 422 each

    However, the number of trees may be eight times higher than previously thought
    60 years of Scalextric: Model cars are now stuffed with as much tech as real ones

    60 years of Scalextric

    Model cars are now stuffed with as much tech as real ones
    Theme parks continue to draw in thrill-seekers despite the risks - so why are we so addicted?

    Why are we addicted to theme parks?

    Now that Banksy has unveiled his own dystopian version, Christopher Beanland considers the ups and downs of our endless quest for amusement
    Tourism in Iran: The country will soon be opening up again after years of isolation

    Iran is opening up again to tourists

    After years of isolation, Iran is reopening its embassies abroad. Soon, there'll be the chance for the adventurous to holiday there
    10 best PS4 games

    10 best PS4 games

    Can’t wait for the new round of blockbusters due out this autumn? We played through last year’s offering
    Transfer window: Ten things we learnt

    Ten things we learnt from the transfer window

    Record-breaking spending shows FFP restraint no longer applies
    Migrant crisis: UN official Philippe Douste-Blazy reveals the harrowing sights he encountered among refugees arriving on Lampedusa

    ‘Can we really just turn away?’

    Dead bodies, men drowning, women miscarrying – a senior UN figure on the horrors he has witnessed among migrants arriving on Lampedusa, and urges politicians not to underestimate our caring nature
    Nine of Syria and Iraq's 10 world heritage sites are in danger as Isis ravages centuries of history

    Nine of Syria and Iraq's 10 world heritage sites are in danger...

    ... and not just because of Isis vandalism
    Girl on a Plane: An exclusive extract of the novelisation inspired by the 1970 Palestinian fighters hijack

    Girl on a Plane

    An exclusive extract of the novelisation inspired by the 1970 Palestinian fighters hijack
    Why Frederick Forsyth's spying days could spell disaster for today's journalists

    Why Frederick Forsyth's spying days could spell disaster for today's journalists

    The author of 'The Day of the Jackal' has revealed he spied for MI6 while a foreign correspondent